2014 will be marked as a transition year for the Japanese Pharma industry – the year is bound to be painful both for innovators and generic companies due to the new regulations. We find these regulations to be ‘decisive’ in spurring generic penetration significantly, with the main beneficiary being the Japanese government (or society) and not the generic companies.
The implications of new price-reversions are going to have many facets and will change conventional business models. We expect many support services industries – CMOs, CROs,
We also expect consolidation and M&A activities to spur in Japan. Innovation Takes the Driver’s Seat: While the new regulations will change the current business philosophy of doing business in patent expired space (>45% to total Japan market), the policymakers also discourage ‘me too’ innovations at the same time. The regulators however, tend to support the ‘first time in the world’ level innovations by providing ‘innovation premiums’. Japanese innovators will now become more serious and selective in their R&D approach.
We find some of the candidates to remain in the limelight in 2014 along with some new additions – Edoxaban (Daiichi Sankyo), Invokana (Mitsubishi Tanabe), Dolutegravir (Shionogi), BBI-608 (Dainippon Sumitomo), Vedolizumab (Takeda), Xtandi (Astellas), Nivolumab (Ono) to hand-pick a few of them.
The reports explain detail analysis